Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 2/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23031851 | 0.77 | LPL (0.37) | LPLLIPG | |
| SCHEMBL16897454 | 0.75 | ESR2 (0.33) | LPLLIPGESR2 | |
| SCHEMBL20539899 | 0.74 | LPL (0.38) | LPLLIPG | |
| SCHEMBL1988136 | 0.74 | LPL (0.38) | LPLLIPG | |
| SCHEMBL14332408 | 0.73 | LPL (0.42) | LPLLIPG | |
| SCHEMBL30101113 | 0.71 | CYP2A6 (0.35) | LPLLIPGESR2 | |
| SCHEMBL931715 | 0.71 | CYP2A6 (0.35) | LPLLIPGESR2 | |
| SCHEMBL7960738 | 0.71 | ESR2 (0.41) | LPLLIPGESR2 | |
| SCHEMBL21052188 | 0.70 | LPL (0.39) | LPLLIPG | |
| SCHEMBL25064189 | 0.70 | LPL (0.35) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4433059-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | Erasca, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| US-20230365553-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230365553-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230365553-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-11-16 | — | — | US | disclosed |
| WO-2023215494-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| CN-116261452-A | Compounds and compositions for the treatment of diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| EP-4182030-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| WO-2023087027-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2022015979-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2022-01-20 | — | — | WO | disclosed |
| US-20170327497-A1 | SUBSTITUTED 6-AZA-ISOINDOLIN-1-ONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-16 | — | — | US | disclosed |
| US-9663514-B2 | Substituted 6-aza-isoindolin-1-one derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-30 | — | — | US | disclosed |
| EP-2723739-B1 | SUBSTITUTED 6-AZA-ISOINDOLIN-1-ONE DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2016-08-24 | — | — | EP | disclosed |
| US-20150274723-A1 | SUBSTITUTED 6-AZA-ISOINDOLIN-1-ONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-01 | — | — | US | disclosed |
| US-9056873-B2 | Substituted 6-aza-isoindolin-1-one derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-16 | — | — | US | disclosed |
| US-20140206680-A1 | SUBSTITUTED 6-AZA-ISOINDOLIN-1-ONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-24 | — | — | US | disclosed |
| EP-2723739-A1 | SUBSTITUTED 6-AZA-ISOINDOLIN-1-ONE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2014-04-30 | — | — | EP | disclosed |
| WO-2012177714-A1 | SUBSTITUTED 6-AZA-ISOINDOLIN-1-ONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-27 | — | — | WO | disclosed |
| US-7514563-B2 | Producing cyano-substituted pyridine, pyrrole, furan, thiophene or benzene boranes by reacting a cyanoarene with a BH or a HBBH compound, especially 4,4,5,5-tetramethyl-1,3,2-dioxborolane or its dimer, in the presence of an organo-phosphorus or -nitrogen iridium complex; drug intermediates | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514563-B2 | Producing cyano-substituted pyridine, pyrrole, furan, thiophene or benzene boranes by reacting a cyanoarene with a BH or a HBBH compound, especially 4,4,5,5-tetramethyl-1,3,2-dioxborolane or its dimer, in the presence of an organo-phosphorus or -nitrogen iridium complex; drug intermediates | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2009-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ULK1, ULK2, ULK3 | LPL 4403/4885LIPG 3529/4885ESR2 2354/4885 |
| US-20150274723-A1 | SUBSTITUTED 6-AZA-ISOINDOLIN-1-ONE DERIVATIVES | SYK, MYD88, BTK | LPL 4095/4885LIPG 2591/4885ESR2 1439/4885 |
| US-20140206680-A1 | SUBSTITUTED 6-AZA-ISOINDOLIN-1-ONE DERIVATIVES | SYK, MYD88, BTK | LPL 4095/4885LIPG 2591/4885ESR2 1439/4885 |
| US-20170327497-A1 | SUBSTITUTED 6-AZA-ISOINDOLIN-1-ONE DERIVATIVES | SYK, MYD88, BTK | LPL 4095/4885LIPG 2591/4885ESR2 1439/4885 |
| US-20230365553-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | LPL 1616/4885LIPG 164/4885ESR2 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.